Home > Publications database > A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk. > print

001     141775
005     20240229112526.0
024 7 _ |a 10.1158/0008-5472.CAN-18-2318
|2 doi
024 7 _ |a pmid:30425058
|2 pmid
024 7 _ |a 0008-5472
|2 ISSN
024 7 _ |a 0099-7013
|2 ISSN
024 7 _ |a 0099-7374
|2 ISSN
024 7 _ |a 1538-7445
|2 ISSN
024 7 _ |a altmetric:51244131
|2 altmetric
037 _ _ |a DKFZ-2018-02044
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Travis, Ruth C
|b 0
245 _ _ |a A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk.
260 _ _ |a Philadelphia, Pa.
|c 2019
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1554367666_5219
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between pre-diagnostic concentrations of 25-hydroxyvitamin D (25(OH)D) and 1,25(OH)2D and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH)2D for up to 13,462 men with incident prostate cancer and 20,261 control participants. Odds ratios (OR) for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (multivariable-adjusted OR comparing highest versus lowest study-specific fifth was 1.22, 95% CI 1.13-1.31; P trend<0.001). However, this association varied by disease aggressiveness (Pheterogeneity=0.014); higher circulating 25(OH)D was associated with a higher risk of non-aggressive disease (OR per 80 percentile increase=1.24, 1.13-1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78-1.15). 1,25(OH)2D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of non-aggressive prostate cancer may be influenced by detection bias.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Perez-Cornago, Aurora
|0 0000-0002-5652-356X
|b 1
700 1 _ |a Appleby, Paul N
|b 2
700 1 _ |a Albanes, Demetrius
|b 3
700 1 _ |a Joshu, Corinne E
|0 0000-0002-5100-172X
|b 4
700 1 _ |a Lutsey, Pamela L
|0 0000-0002-1572-1340
|b 5
700 1 _ |a Mondul, Alison M
|b 6
700 1 _ |a Platz, Elizabeth A
|b 7
700 1 _ |a Weinstein, Stephanie J
|0 0000-0002-3834-1535
|b 8
700 1 _ |a Layne, Tracy M
|b 9
700 1 _ |a Helzlsouer, Kathy J
|b 10
700 1 _ |a Visvanathan, Kala
|b 11
700 1 _ |a Palli, Domenico
|0 0000-0002-5558-2437
|b 12
700 1 _ |a Peeters, Petra H
|b 13
700 1 _ |a Bueno-de-Mesquita, Bas
|b 14
700 1 _ |a Trichopoulou, Antonia
|b 15
700 1 _ |a Gunter, Marc J
|b 16
700 1 _ |a Tsilidis, Konstantinos K
|b 17
700 1 _ |a Sanchez, Maria-Jose
|b 18
700 1 _ |a Olsen, Anja
|b 19
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 20
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 21
|u dkfz
700 1 _ |a Perna, Laura
|0 P:(DE-He78)d9d72431035d8535d1b65ce9a01c2f60
|b 22
|u dkfz
700 1 _ |a Holleczek, Bernd
|b 23
700 1 _ |a Knekt, Paul
|b 24
700 1 _ |a Rissanen, Harri
|b 25
700 1 _ |a Yeap, Bu B
|0 0000-0002-7612-5892
|b 26
700 1 _ |a Flicker, Leon
|b 27
700 1 _ |a Almeida, Osvaldo P
|b 28
700 1 _ |a Wong, Yuen Yee Elizabeth
|b 29
700 1 _ |a Chan, June M
|b 30
700 1 _ |a Giovannucci, Edward L
|b 31
700 1 _ |a Stampfer, Meir J
|b 32
700 1 _ |a Ursin, Giske
|0 0000-0002-0835-9507
|b 33
700 1 _ |a Gislefoss, Randi E
|b 34
700 1 _ |a Bjørge, Tone
|b 35
700 1 _ |a Meyer, Haakon E
|b 36
700 1 _ |a Blomhoff, Rune
|0 0000-0001-7329-3615
|b 37
700 1 _ |a Tsugane, Shoichiro
|b 38
700 1 _ |a Sawada, Norie
|b 39
700 1 _ |a English, Dallas R
|b 40
700 1 _ |a Eyles, Darryl W
|b 41
700 1 _ |a Heath, Alicia K
|0 0000-0001-6517-1300
|b 42
700 1 _ |a Williamson, Elizabeth J
|0 0000-0001-6905-876X
|b 43
700 1 _ |a Manjer, Jonas
|b 44
700 1 _ |a Malm, Johan
|b 45
700 1 _ |a Almquist, Martin
|b 46
700 1 _ |a Le Marchand, Loic
|b 47
700 1 _ |a Haiman, Christopher A
|b 48
700 1 _ |a Wilkens, Lynne R
|b 49
700 1 _ |a Schenk, Jeannette M
|b 50
700 1 _ |a Tangen, Cathy M
|b 51
700 1 _ |a Black, Amanda
|b 52
700 1 _ |a Cook, Michael B
|b 53
700 1 _ |a Huang, Wen-Yi
|0 0000-0002-4440-3368
|b 54
700 1 _ |a Ziegler, Regina G
|0 0000-0002-5100-9852
|b 55
700 1 _ |a Martin, Richard M
|0 0000-0002-7992-7719
|b 56
700 1 _ |a Hamdy, Freddie C
|b 57
700 1 _ |a Donovan, Jenny L
|0 0000-0002-6488-5472
|b 58
700 1 _ |a Neal, David E
|0 0000-0002-6033-5086
|b 59
700 1 _ |a Touvier, Mathilde
|b 60
700 1 _ |a Hercberg, Serge
|b 61
700 1 _ |a Galan, Pilar
|b 62
700 1 _ |a Deschasaux, Mélanie
|b 63
700 1 _ |a Key, Timothy J
|0 0000-0003-2294-307X
|b 64
700 1 _ |a Allen, Naomi E
|0 0000-0003-1938-5038
|b 65
773 _ _ |a 10.1158/0008-5472.CAN-18-2318
|g p. canres.2318.2018 -
|0 PERI:(DE-600)2036785-5
|n 1
|p 274-285
|t Cancer research
|v 79
|y 2019
|x 1538-7445
909 C O |p VDB
|o oai:inrepo02.dkfz.de:141775
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)d9d72431035d8535d1b65ce9a01c2f60
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER RES : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER RES : 2017
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l Klinische Epidemiologie und Alternsforschung
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21